The findings align with recent studies that showed similar results when comparing SGLT2 inhibitors and GLP-1RAs in patients with type 2 diabetes, where the NAFLD status was unknown [30]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.